Physician profile
Devin Haub
NPI 1952835910
$3,004.25
in general payments reported to CMS, 2019-2025
21 companies · $713 in 2025
The $713 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $299 · 2023: $1,139 · 2024: $854 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.27 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Lilly USA, LLC | $448.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $220.08 | 2023-2025 | |
| Amgen INC. | $177.55 | 2022-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $152.65 | 2023-2025 | |
| Novo Nordisk INC | $132.06 | 2022-2025 | Wegovy |
| Axsome Therapeutics, INC. | $93.01 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $82.27 | 2022-2023 | Trelegy Ellipta |
| Dexcom, INC. | $70.62 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $47.31 | 2024-2025 | Voquezna |
| Abbott Laboratories | $38.67 | 2023-2024 | Freestyle Libre 3 |
| Stryker Corporation | $35.87 | 2022 | |
| Acella Pharmaceuticals, LLC | $29.92 | 2024-2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $20.10 | 2023 | Rexulti, Abilify Maintena |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $17.63 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $16.32 | 2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $15.90 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $13.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Haub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.